These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15617169)

  • 21. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Frequency and causes of premature termination (drop-out) during in-patient opiate detoxification].
    Gössling HW; Gunkel S; Schneider U; Melles W
    Fortschr Neurol Psychiatr; 2001 Oct; 69(10):474-81. PubMed ID: 11602924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.
    DeFlavio JR; Rolin SA; Nordstrom BR; Kazal LA
    Rural Remote Health; 2015; 15():3019. PubMed ID: 25651434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary healthcare-based integrated care with opioid agonist treatment: First experience from Ukraine.
    Morozova O; Dvoriak S; Pykalo I; Altice FL
    Drug Alcohol Depend; 2017 Apr; 173():132-138. PubMed ID: 28242537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brief Report: Low-Barrier Buprenorphine Initiation Predicts Treatment Retention Among Latinx and Non-Latinx Primary Care Patients.
    Lee CS; Rosales R; Stein MD; Nicholls M; O'Connor BM; Loukas Ryan V; Davis EA
    Am J Addict; 2019 Sep; 28(5):409-412. PubMed ID: 31251426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Opiate substitution treatment's cycles in a five-year followed-up cohort in ambulatory practice].
    Dupouy J; Bez J; Barsony J; Oustric S; Lapeyre-Mestre M
    Therapie; 2013; 68(3):155-61. PubMed ID: 23886460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Substitution treatment for opiate dependence: survey of community pharmacies in Aquitaine].
    Jeantaud I; Haramburu F; Bégaud B
    Therapie; 1999; 54(2):251-5. PubMed ID: 10394262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Psychopathology of the misuse of Subutex®: The Popeye syndrome].
    Békaert J; Podevin G
    Encephale; 2015 Jun; 41(3):229-37. PubMed ID: 25212472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Opioid substitution therapy in France: a physician's overview].
    Michel L
    Ann Pharm Fr; 2009 Sep; 67(5):369-73. PubMed ID: 19695374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Investigation of the medical and social situation of patients managed by opiate replacement regimens for over 10 years by their GP].
    Messaadi N; Favre J; Rolland B; Cottencin O; Calafiore M; Stalnikiewicz B; Berkhout C
    Therapie; 2016 Oct; 71(5):439-446. PubMed ID: 27203162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging adult age status predicts poor buprenorphine treatment retention.
    Schuman-Olivier Z; Weiss RD; Hoeppner BB; Borodovsky J; Albanese MJ
    J Subst Abuse Treat; 2014 Sep; 47(3):202-12. PubMed ID: 24953168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Maintenance treatment with high-dose buprenorphine: are the recommendations being followed?].
    Seyer D; Dif C; Balthazard G; Sciortino V
    Therapie; 1998; 53(4):349-54. PubMed ID: 9806004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of early childhood trauma on retention and phase advancement in an outpatient buprenorphine treatment program.
    Kumar N; Stowe ZN; Han X; Mancino MJ
    Am J Addict; 2016 Oct; 25(7):542-8. PubMed ID: 27629823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Addictive behavior after starting buprenorphine maintenance treatment].
    Fanello S; Daoud S; Panici JY; Parot E; Hitoto H; Garnier F
    Presse Med; 2006 Feb; 35(2 Pt 1):212-8. PubMed ID: 16493349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Buprenorphine: blending practice and research.
    Ling W; Smith D
    J Subst Abuse Treat; 2002 Sep; 23(2):87-92. PubMed ID: 12220606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Dependence on psychotropic drugs and substitution treatment: recent trends. The OPPIDUM study of the Centers for Evaluation and Information on Drug Dependence (CEIP), October 1997].
    Thirion X; Micallef J; Guet F; Delarozière JC; Arditti J; Huntsman A; Sanmarco JL; Lagier G
    Therapie; 1999; 54(2):243-9. PubMed ID: 10394261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using Shared Medical Appointments to Increase Access to Buprenorphine Treatment.
    Roll D; Spottswood M; Huang H
    J Am Board Fam Med; 2015; 28(5):676-7. PubMed ID: 26355141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine.
    Harris DS; Jones RT; Welm S; Upton RA; Lin E; Mendelson J
    Drug Alcohol Depend; 2000 Dec; 61(1):85-94. PubMed ID: 11064186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of high dose buprenorphine treatments of opiate dependent outpatients in four healthcare networks.
    De Ducla M; Gagnon A; Mucchielli A; Robinet S; Vellay A
    Ann Med Interne (Paris); 2000 Oct; 151 Suppl B():B9-15. PubMed ID: 11104938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trends in opiate and opioid poisonings in addicts in north-east Paris and suburbs, 1995-99.
    Gueye PN; Megarbane B; Borron SW; Adnet F; Galliot-Guilley M; Ricordel I; Tourneau J; Goldgran-Toledano D; Baud FJ
    Addiction; 2002 Oct; 97(10):1295-304. PubMed ID: 12359034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.